About Salvia Jain, MD

Dr. Jain earned her medical degree from Mahatma Gandhi Missions Medical College, Mumbai and Christian Medical College, Vellore. She completed a residency in Internal Medicine at Tufts Medical Center in Boston, followed by a fellowship in Hematology and Oncology at the New York University Langone’s Cancer Center and subspecialty fellowship in cellular therapy and stem cell transplantation at the Stanford Blood and Bone Marrow Transplant Program. Dr. Jain is board certified in Hematology and Medical Oncology. Dr. Jain's clinical interests are in lymphoid malignancies, including all non-Hodgkin lymphomas, with particular focus in T-cell lymphomas. Dr Jain leads an active translational and clinical research program in T-cell lymphomas centered around understanding myeloid biology in the laboratory, dissecting mechanisms of resistance to novel therapeutics in T-cell lymphomas, and clinical development of new therapies involving immune checkpoints and epigenetic modifiers. She is a member of the American Society of Hematology and the American Society of Clinical Oncology, and American Association for Cancer Research. Dr. Jain is the recipient of several federal and foundation young investigator and career development awards, author of numerous manuscripts and book chapters on lymphoma, and lectures.

Departments, Centers, & Programs:

Clinical Interests:



Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Fax: 617-726-8330

Medical Education

  • MBBS, Mahatma Gandhi Missions Medical College
  • Residency, Tufts Medical Center
  • Fellowship, New York University Medical Center
  • Fellowship, Stanford Hospital and Clinics

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr Jain's preclinical research has been translated into several multicenter clinical trials including combinations of HDAC inhibitors with anti-folates, Mucin-1 inhibitor with DNA methyltransferase inhibitors and most recently CD47-SIRPa antagonists with anti-CCR4 antibodies. She leads numerous investigator-initiated clinical trials of novel agents and their combinations including large national and global cohort-based studies for patients with T-cell lymphomas. On the laboratory side she utilizes a spectrum of single cell technologies and diverse spectrum of patient-derived and transgenic mouse models to define mechanisms underlying response resistance to immunotherapeutics in T-cell lymphomas. The laboratory works across a wide range of areas such as delineating molecular mechanisms of response and resistance to CD47 blocking therapies, investigating novel checkpoint strategies, and elucidating regulators of phagocytosis in T-cell lymphomas.


Reviews: Comments and Ratings